SUPERNUS PHARMACEUTICALS, INC. Inventory Write-down
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Inventory Write-down of $5.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2026-06-30 was $4.05M, a 340.11% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2026-03-31 was $1.81M, a 231.81% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2025-12-31 was $698.00K, a 89.86% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2025-09-30 was -$239.00K.
- SUPERNUS PHARMACEUTICALS, INC. inventory write-down for fiscal 2025 was $1.93M, a 78.30% decline from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. inventory write-down for fiscal 2024 was $8.88M, a 10.63% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. inventory write-down for fiscal 2023 was $8.02M, a 23.17% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. inventory write-down for fiscal 2022 was $10.44M.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $5.86M 10-Q · filed 2026-08-03 | $6.56M derived: sum of 3 quarters · filed 2026-08-03 | $6.32M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $1.81M 10-Q · filed 2026-05-05 | $2.51M derived: sum of 2 quarters · filed 2026-05-05 | $2.27M derived: sum of 3 quarters · filed 2026-05-05 | $3.19M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $698.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $459.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.38M derived: sum of 3 quarters · filed 2026-08-03 | $1.93M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$239.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $681.00K derived: sum of 2 quarters · filed 2026-08-03 | $1.23M 10-Q · filed 2025-11-06 | $8.11M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $920.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.47M 10-Q · filed 2026-08-03 | $8.35M derived: sum of 3 quarters · filed 2026-08-03 | $8.32M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $547.00K 10-Q · filed 2026-05-05 | $7.43M derived: sum of 2 quarters · filed 2026-05-05 | $7.40M derived: sum of 3 quarters · filed 2026-05-05 | $8.69M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $6.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.85M derived: sum of 2 quarters · filed 2026-03-02 | $8.15M derived: sum of 3 quarters · filed 2026-03-02 | $8.88M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.26M derived: sum of 2 quarters · filed 2025-11-06 | $1.99M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.02M 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $730.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $8.02M 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $10.44M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |